Oculis posts widening quarterly loss as R&D spend climbs

Oculis Holding (Nasdaq: OCS) reported a net loss of $36 million for the first quarter of 2025, more than double the loss in the same period last year, as the Swiss biopharma stepped up investment in its late-stage pipeline.

Operating expenses for the quarter rose 30% to $22 million, driven by a 36% increase in research and development spending. The biggest outlay came from the company’s lead candidate, OCS-01, a topical eye drop in Phase III testing for diabetic macular oedema. General and administrative costs rose 17%.

The company, which has no product revenue, posted grant income of $310,000, up 28% from a year ago. Cash and short-term investments totaled $206 million at the end of March, bolstered by a $100 million public offering in February.